PremiumCompany AnnouncementsBiofrontera Receives Nasdaq Non-Compliance Notice Biofrontera, Inc. Earnings Call: Growth Amid Challenges Biofrontera Inc. price target lowered to $2.75 from $7 at Benchmark PremiumThe FlyBiofrontera Inc. announces patent protection on Ameluz until 2043 Biofrontera Faces Nasdaq Non-Compliance Notice Is BFRI a Buy, Before Earnings? PremiumPre-EarningsBFRI Upcoming Earnings Report: What to Expect? Biofrontera completes patient enrollment in Phase 3 study of Ameluz Biofrontera Inc. files to sell 5.72M shares of common stock for holders